Compare BLND & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLND | ESPR |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.7M | 898.5M |
| IPO Year | 2021 | 2013 |
| Metric | BLND | ESPR |
|---|---|---|
| Price | $2.96 | $3.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $4.80 | ★ $6.67 |
| AVG Volume (30 Days) | 2.0M | ★ 5.6M |
| Earning Date | 02-26-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $167,532,000.00 | ★ $303,802,000.00 |
| Revenue This Year | N/A | $26.11 |
| Revenue Next Year | $19.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.61 | 2.83 |
| 52 Week Low | $2.50 | $0.69 |
| 52 Week High | $4.49 | $4.18 |
| Indicator | BLND | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 32.93 |
| Support Level | $2.95 | $3.00 |
| Resistance Level | $3.37 | $4.18 |
| Average True Range (ATR) | 0.16 | 0.23 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 0.02 | 4.26 |
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.